Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection.
Disease progression of human immunodeficiency virus type 1 (HIV-1) is associated with immune activation. Activation indices are higher during coinfection of hepatitis C virus (HCV) and HIV. The effect of immune activation on interferon α (IFN-α) therapy response is unknown. We evaluated soluble CD14 (sCD14) and natural killer (NK)-cell subsets at baseline, and during pegIFN-α2a/ribavirin therapy in HCV-HIV coinfection. The sCD14 level increased during therapy. Baseline sCD14 positively correlated with baseline HCV level and CD16(+)56(-) NK-cell frequency, and both sCD14 and CD16(+)56(-) NK cells correlated negatively with magnitude of HCV decline. IL28B genotype was associated with therapy response but not sCD14 or CD16(+)56(-) NK frequency. Markers of innate immune activation predict poor host response to IFN-α-based HCV therapy during HCV-HIV coinfection.
Department of Medicine, Divisions of Infectious and Rheumatic Diseases, Case Western Reserve University, Center for AIDS Research, University Hospitals of Cleveland and VA Medical Center, Cleveland, OH 44106, USA. dda3@case.edu
Donald D
DD
Anthony
Sara J
SJ
Conry
Kathy
K
Medvik
M R
MR
Sandhya Rani
Yngve
Y
Falck-Ytter
Ronald E
RE
Blanton
Michael M
MM
Lederman
Benigno
B
Rodriguez
Alan L
AL
Landay
Johan K
JK
Sandberg
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D019002:CD56 Antigen / Q000378:metabolism; D060085:Coinfection; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism; D018950:Lipopolysaccharide Receptors / Q000378:metabolism; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use; D017452:Receptors, IgG / Q000378:metabolism; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use
D000998:Antiviral Agents; D019002:CD56 Antigen; D016898:Interferon-alpha; D018950:Lipopolysaccharide Receptors; C522918:NCAM1 protein, human; D017452:Receptors, IgG; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a